MoonLake Immunotherapeutics is working with an investment bank to explore a sale and is having early-stage conversations with drugmakers interested in a potential acquisition, David Carnevali of Reuters reports, citing people familiar with the matter. The sources added that no deal is certain, notes Carnevali. Shares of MoonLake are up 11% to $55.79 following the report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MLTX:
- MoonLake price target raised to $65 from $29 at Cantor Fitzgerald
- MoonLake Immunotherapeutics 8M share Secondary priced at $50.00
- MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
- MoonLake Immunotherapeutics price target raised to $61 from $33 at Wedbush
- MoonLake Immunotherapeutics price target raised to $68 from $36 at BTIG